Your search returned 2 results.

Results
	1.	Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. [electronic resource] by Wongchenko, Matthew J Ribas, Antoni Dréno, Brigitte Ascierto, Paolo A McArthur, Grant A Gallo, Jorge D Rooney, Isabelle A Hsu, Jessie Koeppen, Hartmut Yan, Yibing Larkin, James Producer: 20190207 In: Pigment cell & melanoma research vol. 31 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. [electronic resource] by Buchanan, Sean G Hendle, Jorg Lee, Patrick S Smith, Christopher R Bounaud, Pierre-Yves Jessen, Katti A Tang, Crystal M Huser, Nanni H Felce, Jeremy D Froning, Karen J Peterman, Marshall C Aubol, Brandon E Gessert, Steve F Sauder, J Michael Schwinn, Kenneth D Russell, Marijane Rooney, Isabelle A Adams, Jason Leon, Barbara C Do, Tuan H Blaney, Jeff M Sprengeler, Paul A Thompson, Devon A Smyth, Lydia Pelletier, Laura A Atwell, Shane Holme, Kevin Wasserman, Stephen R Emtage, Spencer Burley, Stephen K Reich, Siegfried H Producer: 20100324 In: Molecular cancer therapeutics vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search